We redeveloped and validated two anti-human IFNβ luciferase reporter-gene assays.
The optimal serum concentration in regards to sensitivity and recovery was 2.5%.
A floating cut-point was implemented to identify IFNβ specific NAbs.
The assays demonstrated high specificity and acceptable sensitivity.